Undisclosed tau antibody therapeutic / Axon Neurosci - LARVOL DELTA

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217. (PubMed, Alzheimers Res Ther) - P2 | "These results suggest that AADvac1 tau immunotherapy can reduce plasma biomarkers of neurodegeneration and neuroinflammation. These findings and possible observations on brain atrophy and cognition are hypothesis-generating and warrant further evaluation in a larger clinical trial."

Biomarker • Clinical • IO biomarker • Journal • P2 data • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Inflammation • GFAP • Plasma NfL

Tau vaccine AADvac1 demonstrates clinical and biomarker efficacy on patients with plasma p-tau217 defined Alzheimer's disease in Phase II clinical trial: post hoc analysis (CTAD 2023) - P2 | "Tau-targeted active immunotherapy with AADvac1 showed significant treatment effects in biomarker-confirmed AD patients on cognitive and neurodegeneration-related biomarker endpoints. The response to treatment was directly related to the levels of AADvac1-induced anti-tau antibodies. These findings support a Phase IIb clinical trial on A+T+ biomarker-confirmed patients with early AD."

Biomarker • Clinical • IO biomarker • Late-breaking abstract • P2 data • Retrospective data • Alzheimer's Disease • CNS Disorders • Aβ42 • NEFL • Plasma NfL • p-tau181